(1S,2R)-Bortezomib-d5
CAS: 1132709-16-0
Ref. 3D-HVB70916
5mg | Descontinuado | ||
10mg | Descontinuado | ||
25mg | Descontinuado | ||
50mg | Descontinuado | ||
100mg | Descontinuado |
Informação sobre produto
(1S,2R)-Bortezomib-d5 is a modified form of bortezomib that has been radiolabeled with d5. It is an apoptotic agent that inhibits the proteasome pathway and induces apoptosis. Bortezomib-d5 has shown promising results in clinical trials for the treatment of lymphocytic leukemia, chronic lymphocytic leukemia, and multiple myeloma. The drug causes thrombocytopenia as a toxic effect.